Press Releases | Clarus Therapeutics, Inc

Skip to main navigation

Investor Overview
News & Events
- Press Releases
- Events and Presentations
Stock Information
Corporate Governance
Financials & Filings
- SEC Filings
- Quarterly & Annual Reports
IR Resources
- Email Alerts
- Contact IR

Press Releases

Year

May 18, 2022

Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)

May 16, 2022

Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results

May 12, 2022

Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results

May 10, 2022

Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis

May 09, 2022

Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting

Apr 28, 2022

Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)

Apr 27, 2022

Clarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public Offering

Apr 25, 2022

Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offering

Apr 19, 2022

Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the Androgen Society 4th Annual Meeting

Mar 30, 2022

Clarus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 15

2022 Copyright

Search Investor Relations